China NMPA Drug Inspection - Guangxi Ritian Pharmaceutical Group Co., Ltd. - Antibacterial and anti-inflammatory capsules
China NMPA drug inspection for Guangxi Ritian Pharmaceutical Group Co., Ltd. published December 25, 2024. Drug: Antibacterial and anti-inflammatory capsules. The National Medical Products Administration (NMPA) issued Announcement No. 58 on December 25, 2024, identifying 27 batc
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Guangxi Ritian Pharmaceutical Group Co., Ltd. published December 25, 2024. Drug: Antibacterial and anti-inflammatory capsules. The National Medical Products Administration (NMPA) issued Announcement No. 58 on December 25, 2024, identifying 27 batc
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox